home / stock / absi / absi news

ABSI News and Press, Absci Corporation From 02/22/24

Stock Information
Company Name: Absci Corporation
Stock Symbol: ABSI
Market: NASDAQ
Website: absci.com
Menu
ABSI ABSI Quote ABSI Short ABSI News ABSI Articles ABSI Message Board
Get ABSI Alerts

News, Short Squeeze, Breakout and More Instantly...
ABSI - Obesity drugs to expand U.S. GDP by 1% in the coming years: Goldman Sachs

2024-02-22 14:41:34 ET More on Amgen, Eli Lilly, etc. Pfizer's Post-Pandemic Pivot Pfizer: Turnaround Is Gaining Momentum Eli Lilly: Yes, It Is Too Late To Join The Party Novo to face Wegovy competition in India as local versions loom: Reuters Weight-...
ABSI - Absci begins IND-enabling studies for ABS-101 antibody designed using gen AI

2024-02-21 07:46:16 ET More on Absci Absci hits new 52-week high as race for AI drug discovery heats up KeyBanc sees opportunity in tech-enabled drug discovery stocks Seeking Alpha’s Quant Rating on Absci Historical earnings data for Absci Fina...

ABSI - Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI

VANCOUVER, Wash. and NEW YORK, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the initiation of IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody designed using Absci’s de ...

ABSI - Absci Appoints Professor Sir Mene Pangalos to its Board of Directors

Sir Pangalos is a distinguished biopharmaceutical executive who led BioPharmaceuticals R&D at AstraZeneca. In addition to joining Absci’s Board, Sir Pangalos will co-chair Absci’s Scientific Advisory Board. VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (N...
ABSI - Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference

Preclinical data support profile for development of a potential best-in-class drug IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after VANCOUVER, Wash. and NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generati...

ABSI - J.P. Morgan event in spotlight as biotech M&A, obesity frenzy, AI pick up

2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...

ABSI - Absci to Participate in the 26th Annual Needham Growth Conference

VANCOUVER, Wash. and NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually in the upcoming 26 th Annual Needham Growth Conference. Absci management is scheduled to ...
ABSI - 24/7 Market News Snapshot 28 Dec 2023

2023-12-28 10:07:56 ET DENVER, Colo., Dec. 28, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; SEALSQ Corp (NASDAQ: LAES), Microbot Medical Inc (NASDAQ: MBOT), Absci Corp(NASDAQ: ABSI), Nova Lifestyle Inc...

ABSI - Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

VANCOUVER, Wash. and NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Absci manageme...

ABSI - Absci hits new 52-week high as AI drug discovery rallies

2023-12-26 13:19:21 ET More on AbCellera Biologics, Absci, etc. Exscientia Looks Promising In AI-Driven Drug Development AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024 Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platf...
Previous 10 Next 10